MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Impact of injection interval on patient satisfaction in the routine treatment of cervical dystonia with abobotulinumtoxinA

R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

Meeting: 2017 International Congress

Abstract Number: 1198

Keywords: Botulinum toxin: Clinical applications: dystonia, Dysport, Dystonia: Treatment

Session Information

Date: Thursday, June 8, 2017

Session Title: Dystonia

Session Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Objective: Evaluate the impact of injection interval on patient satisfaction with abobotulinumtoxinA (AboBoNT-A; Dysport®) over 1 injection cycle in patients with cervical dystonia (CD).

Background: The clinical benefits of botulinum neurotoxin type A (BoNT-A) typically peak within the first 2-3 weeks, and then gradually wear-off over the following months. While patient satisfaction is expected to match this time-course, patient expectations and management experience may also influence treatment satisfaction.

Methods: This analysis of the MetaCD database includes data from 2 of the 3 component observational studies (INTEREST IN CD2 & ANCHOR-CD), which both evaluated patient satisfaction with BoNT-A treatment. Subjects received 1 injection cycle and rated their highest level of satisfaction (i.e. at peak effect) during the treatment cycle. This analysis compared levels of satisfaction of AboBoNT-A-treated subjects categorized by injection interval.

Results: Of 124 AboBoNT-A-treated subjects new to BoNT, 94 (75.8%) were treated with an injection interval of 12-16 weeks, 18 (14.5%) with >16-week interval and 6 (4.8%) with <12-week interval; data were missing for 6 subjects. A further 719 AboBoNT-A-treated subjects had been previously treated with a BoNT. Of these, 487 (67.7%) were treated with an injection interval of 12-16 weeks, 200 (27.8%) with >16-week interval and 20 (2.8%) with <12-week interval; data were missing for 12 subjects. Patient satisfaction was very high across all injection intervals, regardless of previous BoNT treatment [Table 1].

Conclusions: These observations indicate that satisfaction with AboBoNT-A treatment is consistently high. The majority of subjects treated with AboBoNT-A had injection intervals ≥12 weeks, with 27.8% of previously treated subjects having an interval >16 weeks. The lack of subjects with an interval <12 weeks precludes any robust conclusions for this short interval. Factors other than direct AboBoNT-A effect, including patient expectations, may also play a role in the reported satisfaction rates.   

To cite this abstract in AMA style:

R. Trosch, V. Misra, P. Maisonobe, S. Om. Impact of injection interval on patient satisfaction in the routine treatment of cervical dystonia with abobotulinumtoxinA [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/impact-of-injection-interval-on-patient-satisfaction-in-the-routine-treatment-of-cervical-dystonia-with-abobotulinumtoxina/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/impact-of-injection-interval-on-patient-satisfaction-in-the-routine-treatment-of-cervical-dystonia-with-abobotulinumtoxina/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley